Prothena Corporation plc Ordinary Shares PRTA
i
Market dataready · fetched 2026-11-12T15:36:14.996Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T15:31:33.872977189Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T15:36:14.116012+00:00
Prothena Corporation plc Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 5.88 | 564.9% | 45.1% | |||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | 8.08 | 173.9% | 12.0% | |||
| 45Δ | 8.28 | 161.5% | 10.3% | |||
| 50Δ | 8.48 | 149.0% | 8.5% | |||
| 55Δ | 8.69 | 136.6% | 6.7% | |||
| 60Δ | ||||||
| 65Δ | 10.48 | 254.9% | 8.1% | |||
| 70Δ | 7.40 | 425.1% | 18.5% | 10.88 | 238.5% | 6.9% |
| 75Δ | 6.79 | 369.3% | 12.1% | 11.28 | 222.1% | 5.6% |
| 80Δ | 6.38 | 318.5% | 7.9% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.88
- IV
- 564.9%
- B/E move
- 45.1%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.08
- IV
- 173.9%
- B/E move
- 12.0%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.28
- IV
- 161.5%
- B/E move
- 10.3%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.48
- IV
- 149.0%
- B/E move
- 8.5%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.69
- IV
- 136.6%
- B/E move
- 6.7%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.48
- IV
- 254.9%
- B/E move
- 8.1%
70Δ
- Pseudo strike
- 7.40
- IV
- 425.1%
- B/E move
- 18.5%
- Pseudo strike
- 10.88
- IV
- 238.5%
- B/E move
- 6.9%
75Δ
- Pseudo strike
- 6.79
- IV
- 369.3%
- B/E move
- 12.1%
- Pseudo strike
- 11.28
- IV
- 222.1%
- B/E move
- 5.6%
80Δ
- Pseudo strike
- 6.38
- IV
- 318.5%
- B/E move
- 7.9%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 110.00% | |
| 141.98% | |
| 153.23% | |
| 182.99% | |
| 176.75% | |
| 102.51% | |
| 92.49% | |
| 197.72% | |
| 85.45% | |
| 142.96% |
Biotechnology
PTCT
Description unavailable
More →PTGX
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is…
More →PVLA
Palvella Therapeutics, Inc. is an innovative biotechnology firm dedicated to developing transformative therapies for rare genetic disorders resulting from specific gene mutations.…
More →PYPD
PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX) platform to address…
More →PYXS
Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies for treating…
More →QTTB
Q32 Bio Inc. (QTTB) is a pioneering biotechnology firm focused on the development of advanced antibody-based therapies for autoimmune diseases and immune response optimization.…
More →